Dalton Transactions



BODIPY-functionalized 1,10-phenanthroline as long wavelength sensitizers for near-infrared emission of ytterbium (III) ion

Journal:	Dalton Transactions	
Manuscript ID	DT-ART-07-2019-002850.R2	
Article Type:	Paper	
Date Submitted by the Author:	13-Aug-2019	
Complete List of Authors:	Kukoyi, Adedayo; Eastern Illinois University Micheli, Eric; Eastern Illinois University, Chemistry Liu, beibei; Eastern Illinois University He, Hongshan; Eastern Illinois University, Chemistry May, P.; South Dakota State University College of Education and Human Sciences, Physical Chemistry Department of Chemistry	

SCHOLARONE[™] Manuscripts

ARTICLE



Adedayo Kukoyi, ^a Eric A. Micheli, ^a Beibei Liu, ^a Hongshan He, *a and P. Stanley May ^b

sensitizers for near-infrared emission of ytterbium (III) ion

Received 00th January 20xx, Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Two BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) moieties were chemically appended to the 4,7-positions of 1,10phenanhtroline resulting in two new ligands (BODIPY-Phen and 4I-BODIPY-Phen) with strong absorption at 507 nm and 540 nm, respectively. BODIPY-Phen emits strongly centered at 507 nm, whereas the fluorescence of 4I-BODIPY-Phen was completely quenched due to the introduction of four I atoms at its 2,6 positions. Two ligands reacted readily with tris(1,1,1,5,5,5-hexafluoro-2,4-pentanedionate) ytterbium (III) dihydrate through substitution reactions forming eightcoordinate complexes that emits strongly at 976 nm upon excitation at their absorption maximal positions. Both complexes exhibited a lifetime of ~ 11 μ s in dichloromethane at room temperature.

BODIPY-functionalized 1,10-phenanthroline as long wavelength

Introduction

The fluorescence-based diagnosis has emerged as a powerful tool for gaining a greater understanding of structural and functional properties in living systems.^{1, 2} The information provided is crucial to the visualization of biological events, development of new medicines, and assessment of the effectiveness of medical treatments.³⁻⁵ The key to the diagnosis is the sensitivity of the probe. Currently available clinical probes emit in the visible region and their fluorescence spectra overlap with autofluorescence from substrates, which significantly limits test sensitivity.^{5, 6} Most state-of-the-the-art probes also require excitation at a short wavelength, which often results in severe photobleaching of biological substrates. Therefore, it is desirable to develop novel fluorescent probes that emit strongly in the near-infrared (NIR) region under long wavelengths excitation. NIR probes will not only increase sensitivity by eliminating background signals but also provide deep penetration capability for in vivo imaging. Certain lanthanide ions are potential NIR probes.⁷⁻¹⁰ For example, ytterbium (III) displays emission at 980 nm, which is usually realized by a sensitization process (the "antenna effect"). In this process, energy from the excited state (usually a triplet state) of a sensitizer transfers to the excited state of Yb(III) ion. After relaxation to its ground state, NIR emission is produced.11-13

Two challenges have to be addressed in regards to biological applications of NIR emitting lanthanide complexes. The first one is to suppress the fluorescence quenching from vibrations of X-H (X = N, O, C) in the vicinity of the coordination sphere, which

can be partially overcome by the formation of complexes with high coordination numbers.¹³⁻¹⁹ This provides a barrier for the access of solvent molecules to the central lanthanide ion. The second challenge is to broaden the absorption window of ligands toward the red light region.⁷ This will enable the use of long wavelength light sources to reduce the photodegradation, which is significant when a UV or a near UV light source is used. This can be addressed by appending chromophore to a ligandbinding-group (LBG). During the last two decades, numerous attempts have been made and promising results have been obtained.¹³ Among all lanthanide ions, ytterbium (III) exhibits the strongest emission in the NIR region; therefore is a potential candidate for diagnostic applications. However, it is quite challenging to sensitize the Yb (III) ion under long wavelength excitation due to the weak absorption of the ligands that are normally used to form coordination compounds.

BODIPY dyes have been explored as potential sensitizers for Yb(III)-centered NIR emission. BODIPY, abbreviated from 4,4difluoro-4-bora-3a,4a-diaza-s-indacene, is a family of borondipyrromethene compounds that have high absorptivity and tunable spectral characteristics in the visible region.²⁰⁻²⁵ Though the BODIPY core lacks the binding capability to the Yb(III) ion, it can be modified by a lanthanide-binding-group (LBG) to bring the BODIPY close to Yb(III) for sensitizing.²⁶ In 2006, Jean-Claude G. Bünzli et al²⁷ linked a terpyridine to a BODIPY core and prepared its Yb(III) complex, which emitted moderately at 980 nm. We attached an 8-hydroxyquinoline to a BODIPY core and found the resulting Yb(III) complex also emitted at 980 nm upon excitation at 507 nm.28, 29 Its iodinated analog sensitizes effectively with a much longer lifetime upon excitation at 535 nm.²⁸ The enhancement is attributed to an efficient intersystem crossing for a higher triplet yield due to a "heavy atom" effect. Recently, we linked two BODIPY moieties to 1,10phenanthroline and found it can sensitize the ytterbium emission after the coordination to the metal.³⁰ To further our work in this direction, we designed two new BODIPY-modified 1,10-

^{a.}Department of Chemistry and Biochemistry, Eastern Illinois University, Charleston, IL 61920 Email: <u>hhe@eiu.edu</u>, Tel: 1-217-581-6231


^{b.} Department of Chemistry, University of South Dakota, Vermillion, SD 57069.

⁺ Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

ARTICLE

phenanthroline ligands and their interaction with tris(1,1,1,5,5,5)-hexafluoro-2,4-pentanedionate) ytterbium (III) dihydrate, [Yb(HFA)₃(H₂O)₂] as shown in **Scheme 1**. The resulting complexes are eight-coordinate with strong NIR emission in the near-infrared region. In this report, the synthesis, characterization of ligands and their interactions with ytterbium (III) will be discussed.



Experimental Section

Reagent and General procedures

4,7-dimethyl-1,10-phenanthroline (4,7-Me-Phen), SeO₂, BF₃·OEt₂ (48%), HIO₃, I₂, 2,3-dichloro-5,6-dicyano-1,4benzoquinone (DDQ), 2,4-dimethylpyrrole and triethylamine (Et₃N) were obtained commercially and used without further purification. Tris(1,1,1,5,5,5-hexafluoro-2,4-pentanedionate) ytterbium (III) dihydrate ([(HFA)₃Yb(H₂O)₂]) was purchased from the Strem Chemicals, Inc. and was used directly for reactions. Solvents for photophysical studies were ACS grade and ultra-dry in Aeroseal container and used as received. CDCl3 was from the Cambridge Isotope Laboratories with 99.8% D in ampule and used without further purification. Elemental compositions were determined on a Perkin Elmer Series II-2400 CHNS analyser. All other chemicals and solvents for synthesis and purification were analytical grade and used as received. 4,7diformyl-1,10-phenathroline was prepared according to the literature method31 and confirmed by the 1H NMR and MS (Figure S1 – S4).

Synthesis of L1

To a dry dichloromethane (150 mL) solution of 4,7-diformyl-1,10-phenanthroline (346 mg, 2 mmol) was added 2, 4dimethylpyrrole (0.462 ml, 4 mmol) under nitrogen. A drop of BF₃·OEt₂ (~ 0.05 mL) was added and the resulting solution was stirred magnetically at room temperature for 12h. To this solution 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (0.45 g, 2 mmol) was added. After stirring for 2h, triethylamine (4 mL) and BF₃·OEt₂ (4 mL) were added sequentially. The solution became fluorescent immediately under a UV lamp, indicating the formation of the final product. The solution was magnetically stirred for another 6h and the solvent was removed on a rotary evaporator. The residue was re-dissolved in about 5 mL of dichloromethane and was then loaded on column (silica) chromatography and eluted with chloroform. The major band was collected. Yield: 1.05 g, 77%. Anal Found (Calcd.) for C38H34B2F4N6·CH3OH·H2O: C, 65.03 (64.84); H, 5.20 (5.58); N, 11.99 (11.63). ¹H NMR (CDCl₃, ppm) 9.34 (s, 2H), 7.82 (s, 2H), 7.66 (d, 2H), 5.95 (s, 4H), 2.56 (s, 12H), 1.06 (s, 12H). ESI-HR MS: 673.3055 (M+H) (calcd. 673.3045)

Synthesis of L2.

To **L1** (0.473 g, 2.0 mmol) in absolute ethanol was added I₂ (1.06 g, 10 mmol). Then HIO₃ (1.4 g, 8.0 mmol) in water (1.0 mL) was added slowly during 10 minutes. The temperature of the solution was then increased to 60° C and the solution was stirred magnetically for 2h. During the course of the reaction, the fluorescence weakened gradually. After the completion of the reaction, the solvent was removed on a rotary evaporator. The crude product was dissolved in chloroform and purified on a silica column using chloroform as the elute. The major band was collected. The final product was crystallized from CHCl₃/MeOH (v/v: 1:20). Yield: 0.66 g, 80 %. Anal Found (Calcd.) for C₃₈H₃₀B₂F₄I₄N₆: C, 38.51 (38.81); H, 2.99 (2.57); N, 6.98 (7.15). ¹H NMR (CDCl₃, ppm). 9.39 (d, 2H), 7.78 (s, 2H), 7.66 (d, 2H), 2.65 (s, 12H), 1.08 (s, 12H). ESI MS:1176.9 (M+H) (Calcd. 1176.9)

Synthesis of complexes

Two complexes, **L1-Yb** and **L2-Yb**, were prepared in a similar way and a typical one is given for **L1-Yb**. To an ethanol (25 mL) solution of $[Yb(HFA)_3(H_2O)_2]$ (18 mg, 0.022 mmol) was added **L1** (15 mg, 0.022 mmol) in dichloromethane (10 mL). The solution became reddish in colour. The resulting solution was magnetically stirred for 2h at room temperature. The solid was collected, washed with ethanol and dried at 80°C for 12h. **L1-Yb**. Yield: 27 mg, 85%. Anal Calcd. (Found) for C₅₃H₃₇B₂F₂₂N₆O₃Yb, C, 43.31 (43.20); H, 2.54 (2.62), N 5.73 (5.53) ESI MS: 1260.2 (M-HFA) (Calcd. 1260.2); **L2-Yb**, Yield: 37 mg, 87%. Anal Calcd. (Found) for C₅₃H₃₃B₂F₂₂I4N₆O₆Yb, C, 32.31 (32.54); H 1.69 (1.87), N 4.27 (4.35). ESI MS: 1791.8 (M-HFA+CO) (Calcd.1791.9)

X-ray crystallographic analysis

Single crystals of **L1** were obtained by slow evaporation of solvent from a 1:1 (v:v) mixtures of methanol and dichloromethane at room temperature. The crystals were mounted on glass fibres for data collection. Diffraction measurements were made on a CCD-based commercial X-ray diffractometer using Mo K α radiation (λ = 0.71073 Å). The frames were collected at 125K with a scan width 0.3° in ω and integrated with Bruker SAINT Software package using narrow-frame integration algorithm. The unit cell was determined and refined by least squares upon the refinement of XYZ-centroids

of reflections above $20\sigma(I)$. The data were corrected for absorption using the SADABS program.³² The structures were refined on F^2 using the Bruker SHELXTL (version 5.1) software package.³³ Crystal data for **L1**: C₄₀H₄₂B₂F₄N₆O₂, *MW* = 736.42, triclinic, space group = P-1, *a* = 8.5972(5), *b* =10.6737(6), *c* = 21.2322(13) Å, α = 97.6450 (10), β = 97.9850 (10)°, γ = 105.6490 (10), *V* = 1828.00 (19) Å³, *Z* = 2, $\rho_{calcd.}$ = 1.338 Mgm⁻³, μ (Mo-*K* α) = 0.097 mm⁻¹, *F*(000) = 772, *T* = 100 (2) K. 18013 reflections were measured, of which 6419 were unique (*R*int = 0.0345). Final *R*1 = 0.0524 and *wR*² = 0.1344 values were obtained for 4724 observed reflections with *I*>2 σ (*I*), 500 parameters, and GOF = 1.023. CCDC1861312.

Photophysical measurements

Absorption spectra were obtained on a Cary500 UV-visible spectrophotometer at room temperature. Steady-state and timeresolved spectroscopy studies were performed on an FS5 fluorimeter (Edinburg Instruments) with a Xenon arc lamp as a light source. For the visible emission measurements, the slit width for emission and excitation arms was 1 nm. For the NIR emission, the slit width for both emission and excitation was 8 nm. The fluorescence quantum yield, Φ , in the visible region was measured using the following equation:

$$\Phi_{\rm X} = \emptyset_{\rm ST} \left[\frac{Grad_X}{Grad_{ST}} \right] \left[\frac{n_X}{n_{ST}} \right]^2$$

where Grad the gradient from the plot of integrated fluorescence intensity vs absorbance of five samples with different concentrations, and n is the refractive index of the solvents. Rhodamine 6G in ethanol ($\Phi_{ST} = 0.95$, $\lambda_{ex} = 480$ nm) was used as a reference. The decay curves of the samples were also measured on the FS5 (Edinburg Instruments) spectrometer. A laser diode EPL 375 (Edinburg Instruments) with the wavelength of 375 nm was used as light source. The NIR decay curves were acquired using an optical parametric oscillator (OPOTEK Opolette) as an excitation source. NIR emission was detected using a 0.3 m flat-field monochromator (Jobin Yvon TRIAX 320) equipped with a NIR-sensitive photomultiplier tube (Hamamatsu R2658P) in a cooled housing (Products for Research). All spectra were corrected for instrument response. The output from the photomultiplier was pre-amplified (Stanford Research SR 445A) and fed to a multichannel scaler (Stanford Research SR 430) for time-resolved photon counting. The entire system was PC controlled using LabView software.

Theoretical calculation

Calculations for ligands were performed at a density functional theory (DFT) level using Gaussian 09 software.³⁴ The initial input structures were built based upon the crystal structure of a similar complex. The ground state geometries of compounds were optimized using 6-31G(d) as a basis set for C, H, N, B, and F atoms and Midix for I atom and MWB28 for Yb. All other parameters were default set. No negative frequency was found in the final optimized structures. All calculations were carried out in SMD model for mimicking the solvent effect. The calculated absorption data were analyzed by GaussSum software.³⁵

Results and Discussion

Synthesis and Characterization

Ligands (L1 and L2) and complexes (L1-Yb and L2-Yb) are prepared according to a procedure as outlined in Scheme 1. The 4,7-dicarbonyl-1,-10-phenanthroline precursor was prepared by oxidation of 4,7-dimethyl-1,10-phenanthroline with SeO2 in 1,4dioxane with a moderate yield.³⁶ The L1 was prepared by the reaction between 4,7-dicarbonyl-1,10-phenanthroline and 2,4dimethylpyrrole in CH2Cl2 under N2 for 12h in the presence of one drop of BF₃OEt₂, followed by oxidation using 2,3-dichloro-5,6-dicyano-1,4-benzoquinoline (DDQ) and chelating to BF₂ unit in the presence of triethylamine (Et₃N) and BF₃·OEt₂.³⁷ The resulting compound L1 was slightly yellowish. The L1 was then reacted with iodine and HIO3 in ethanol at 60°C to L2 with ~95% yield. The L2 was purplish. The compositions of the two compounds were confirmed by elemental analysis and ¹H NMR (Figures S1- S4). Both ligands were very soluble in CHCl3 and CH₂Cl₂ and slightly soluble in CH₃OH. Samples are not soluble in water, which could be a barrier to medical diagnosis and could be overcome by introducing carboxylic groups to the BODIPY. We are currently working on this direction. The color of the L1 solution was yellowish, whereas the L2 solution was purplish. The structure of L1 was further confirmed by single-crystal Xray diffraction analysis. Its ORTEP diagram is shown in Figure 1. The two BODIPY units, each having a B center with a tetrahedral geometry, are almost perpendicular to the 1,10phenanthroline plan with torsion angles 86.98 (6) and 84.77 (4), respectively. The two BODIPY units are pointing away from two nitrogen atoms (N1 and N2) of the 1,10-phenanthroline unit with a distance of 10.927Å between B1 and B2. There are two methanol molecules in each asymmetric unit, both of which form an intermolecular hydrogen-bond with N1 and N2 from the neighboring unit. The crystals of the L2 diffracted weakly, therefore no X-ray diffraction data were obtained. Synthesis of the complexes, L1-Yb and L2-Yb, was achieved by mixing one with equivalent of ligands $[Yb(HFA)_3(H_2O)_2]$ in dichloromethane. The simple replacement of two H2O molecules by the bidentate ligands afforded the desired complexes. The complexes are soluble in most organic solvents including chloroform, dichloromethane, and toluene and are slightly soluble in methanol and hexane. The compositions of the complexes were confirmed by elemental analysis.




Figure 1. ORTEP diagram of L1 with 50% thermal ellipsoid probability. Hydrogen atoms and two methanol molecules were omitted for clarity.

Photophysical Properties of Ligands

ARTICLE

Absorption and fluorescence properties of the ligands in solution at room temperature were studied. As shown in Figure 2, the L1 exhibits strong absorption in the visible region with a peak position at 507 nm in CH₂Cl₂, which is quite typical for BODIPY dyes. With iodination at C2 and C6 positions in L2, the colour of the solution changed from yellow to pinkish and a strong absorption at 540 nm was observed, and the absorption coefficients are also enhanced. The fluorescence properties of L1 and L2 are different. The L1 gives strong fluorescence at 524 nm with a quantum yield of 84.6% in CH₂Cl₂. The emission wavelength does not change too much in different solvents; however, the quantum yields vary significantly (Table S1) from the lowest quantum yield in DMF (8.7%) to the highest quantum yields in CHCl₃ (88.9%) and CH₂Cl₂ (84.6%). The L2 emits at 569 nm with a quantum yield of about 0.4%, which is significantly lower than that of the L1. This is most likely due to the "heavy atom" effect from introduced iodine atoms as previously observed. The heavy atom facilitated the intersystem crossing for an increased quantum yield of triplet state, which will benefit the sensitization of near-infrared emission of ytterbium (III).




Figure 2. The normalized absorption and fluorescence of L1 and L2 in CH_2Cl_2 at room temperature. The concentration of the all samples is 1×10^{-6} mol/L in CH_2Cl_2 .

Interaction of Ligands with Yb(III)

The interaction of ligands with Yb(III) was first examined from fluorescence titrations of [Yb(HFA)3(H2O)2] solutions with ligands L1 and L2 at room temperature. A typical spectral change of [Yb(HFA)₃(H₂O)₂]/L2 system is shown in Figure 3. The CH₂Cl₂ solution of [Yb(HFA)₃(H₂O)₂] did not give any emission between 900 and 1200 nm upon excitation at 545 nm since [Yb(HFA)₃(H₂O)₂] has no absorption at 545 nm. As L2 was added to the solution, the characteristic emission of Yb (III) in the NIR region was readily observed. The emission intensity increased with the continued addition of L2 until the molar ratio $L2/Yb^{3+}$ reached 1.0, indicating the stoichiometric of replacement of two water molecules by one L2 ligand as shown in the following equation. Similar NIR emission changes were also observed for the L1/Yb³⁺ system. In addition, the reaction between L1 and [Yb(HFA)₃(H₂O)₂] in CDCl₃ was also monitored by ¹H NMR spectroscopy as shown in Figure S5. The L1 gave well-resolved peaks in CDCl3 at 9.34, 7.82, and 7.89 ppm for protons on the phenanthroline fragment, and 5.95 ppm for a proton on the BODIPY ring. After different amount of $[Yb(HFA)_3(H_2O)_2]$ were added, all these peaks except those corresponding to CH₃ were broadened and shifted to low field region due to impact from paramagnetic Yb³⁺ ion. The spectrum did not change after the molar ratio was above 1.0. This result is consistent with emission spectral changes.

$[Yb(HFA)_3(H_2O)_2] + L2 \rightarrow [Yb(HFA)_3(L2)] + 2 H_2O$

The isolated products showed the expected formula of $[Yb(HFA)_3(L1)]$ (L1-Yb) and $[Yb(HFA)_3(L2)]$ (L2-Yb). Their compositions were ascertained by elemental analysis. Single crystals obtained from a solution of $[Yb(HFA)_3(L2)]$ gave poor X-ray diffraction; therefore, no reliable structural information was obtained. However, the geometry-optimized structure of L2-Yb, as shown in Figure 4, revealed an eight-coordination geometry around Yb(III) ion. The phenanthroline unit binds to the Yb(III) through two N atoms with two BODIPY units aligned almost vertically to the phenanthroline unit with dihedral angles 87.27 and 87.60°, respectively. The Yb-O bond length varied from 2.482 to 2.526Å. The two Yb-N bond lengths are 2.700 Å and 2.690Å.




Figure 3. The increase Yb(III) emission (λ_{ex} = 545 nm) intensity of [Yb(HFA)₃(H₂O)₂] in CH₂Cl₂ upon addition of L2 at room temperature. The incubation time was five minutes after addition of L2. The concentration of [Yb(HFA)₃(H₂O)₂] was 2 × 10⁻⁴ mol/L in CH₂Cl₂.






Figure 4. Side-view of geometry-optimized structure of L2-Yb.

Photophysical properties of the complexes

The complexes L1-Yb and L2-Yb exhibit absorption spectra in the visible region that are similar to the corresponding ligands as shown in Figure 5. After forming a complex, the emission wavelength shifted from 524 nm in L1 to 550 nm in L1-Yb and 569 nm in L2 to 584 nm in L2-Yb. The fluorescence of L1 and L2 decreased 95% and 15% after forming the complex with Yb(III) ion, respectively. The characteristic NIR emission spectra that are quite similar to the final spectrum during the titration are also observed. As shown in Figure 5, upon visible excitation, the two complexes exhibit a broad emission feature centered at 1003 nm, which contains three distinct peaks at 976, 1003 and 1019 nm, respectively. These are typical ${}^2F_{5/2} \rightarrow {}^2F_{7/12}$ emission peaks of the ytterbium (III) ion. The emission lifetimes of L1-Yb and L2-Yb from the exponential fitting of their decay curves at 976 nm were 11.2 and 11.3 µs, respectively. The decay curve for L2-Yb is also shown in Figure 6 and Table 1. The calculated intrinsic quantum efficiencies Φ_{Yb} (= τ_{obs}/τ_{rad} , τ_{rad} = 1.2 ms)^{38, 39} are 0.93% and 0.94%, respectively. To verify the origin of sensitization, we recorded the excitation spectra of L1-Yb and L2-Yb ($\lambda_{em} = 976$ nm). As shown in Figure 7, the excitation spectra match the absorption spectra very well, indicating clearly that the BODIPY moiety is responsible for the sensitization of Yb³⁺emission.








Figure 6. Normalized NIR emission spectra of L1-Yb ($\lambda_{ex} = 507 \text{ nm}$) and L2-Yb ($\lambda_{ex} = 547 \text{ nm}$) in CH₂Cl₂ at room temperature. The decay was monitored at 978 upon excitation at the 375 nm.

Table 1. Photophysical properties of L1, L2, L1-Yb and L2-Yb in CH_2Cl_2 at
room temperature.

Compound	Abs (nm)	Emission (\mathcal{N} nm, τ) ^a	QY(%)
L1	507	524 (10 ns)	84.6 ^b
L2	545	569 (<1 ns)	-
L1-Yb	507	550, 976 (11.2 μs), 1003, 1019	0.93°
L2-Yb	545	584, 976 (11.3 μs), 1003, 1019	0.94 °

 $^a\lambda_{ex}=375$ nm for the VIS emission; ^bin CH₂Cl₂; ^ccalculated from $Q_{Yb}=\tau_{obs}/\tau_{rad},\tau_{rad}=1.2$ ms




Figure 7. Excitation and absorption spectra of L2-Yb in CH_2CI_2 at room temperature. The emission wavelength was 976 nm. The excitation spectrum of L1-Yb can be found in Figure S6.

The NIR emission of ytterbium (III) is sensitized by ligand-to-Yb(III) energy transfer. The energy transfer process occurs either from the triplet state of ligand to the excited state of lanthanide (III) (Dexter mechanism) or through dipole-dipole interaction (Förster mechanism).¹³ An early study from Jean-Claude G. Bünzli et al.^{26, 27} revealed that the energy level of the triplet state of BODIPY functionalized terpyridine ligand was ~ 17450 cm⁻¹, which is high enough for energy transfer to Yb(III). The sensitization was proposed to occur by a Dexter electron exchange mechanism. To probe if such a mechanism is also valid for our complexes, we added a slight excess of [Yb(HFA)₃(H₂O)₂] to solutions of ligands L1 and L2 with the same concentration (5.18 \times 10⁻⁶ M) in CH_2Cl_2 in order to generate the L1-Yb and L2-Yb and to ensure that there are no free ligands remaining in solution. The intrinsic fluorescence of ligand L1 decreased 97%, whereas that of ligand L2 decreased 14% (Figures S7 and S8). Such a drastic decrease is a stark contrast to terpyridine and benzoic acid functionalized BODIPY-Yb complexes.^{26, 27} Figure 8 shows that the NIR emission intensities from the L1-Yb and L2-Yb solutions are very similar upon excitation at 514 nm, at which wavelength the two solutions exhibit the same absorbance. Similar emission intensities from the two solutions are also observed when the solutions are excited at their respective absorption peak positions (507 nm and 547 nm), at which the absorbance was adjusted to 0.316 (Figure **S9**). These results demonstrate clearly that the efficient intrinsic intersystem crossing in ligand **L2**, induced by the I atoms, does not affect its ability to sensitize Yb(III) relative to ligand **L1**. Also, the fact that the sensitization efficiency is essentially identical in **L1-Yb** and **L2-Yb** would suggest that the mechanism of sensitization in both complexes is the same. The most straightforward explanation of these observations is that the Yb(III) ion can also induce near the quantitative intersystem crossing in the two complexes, after which, sensitization occurs from the triplet state of the ligand *via* a Dexter mechanism.

ARTICLE




Figure 8. NIR emission spectra of L1-Yb and L2-Yb upon excitation at 514 nm. The two solutions have equal absorbance at 514 nm and show nearly equal emission intensities, indicating that the internal quantum efficiencies of sensitized emission from 1-Yb and 2-Yb are similar.

We performed DFT calculations for ligand L1 and ligand L2 and their complexes, L1-Y and L2-Y, respectively. For the free ligands, the HOMO and LUMO are both located on the BODIPY moieties (Table S2 and S3). The predicted absorption spectra show a red-shift in compound L2 relative to compound L1, which is consistent in trend with the measured absorption spectra. It should be mentioned that BODIPY dyes are notorious in spectral predicting due to the lack of accurate functional and bases sets for calculation.^{40, 41} The triplet level for ligand L1 and L2 are respectively at 782 and 804 nm, which are quite consistent with the measured data by Zhao et al.⁴² The energy levels are positioned at higher energy than the emitting energy level of Yb(III). For the complexes, the electron density at the HOMO (H) and LUMO (L) are high at BODIPY units as shown in Figure 9. Significant electron densities at Yb center are in L+2 and L+3, indicating the energy transfer from BODIPY to the Yb upon excitation.




Figure 9. Electron density distribution profiles of ligand L2 and its Yb(III) complex.

Conclusions

In conclusion, near-infrared emission of ytterbium (III) ion was sensitized successfully by an iodized BODIPY chromophore under excitation at 540 nm. Luminescence lifetimes as long as ~ 11 μ s was observed for 975 nm emission in the iodinated and non-iodinated complexes. The results provide a new strategy for novel optical probes that emit in the NIR region under long wavelength excitation for sensitive biomedical imaging and detection.

Conflicts of interest

There are no conflicts to declare

Acknowledgements


HH thanks National Science Foundation (Award # 1507871) and The Extreme Science and Engineering Discovery Environment (XSEDE) (CHE130116) for financial support of this work. Authors are grateful to a crystallographer for structure refinements during the review of this article.

Notes and references

- J. L. Sessler, W. C. Dow, D. O'Connor, A. Harriman, G. Hemmi, T. D. Mody, R. A. Miller, F. Qing, S. Springs, K. Woodburn and S. W. Young, *J. Alloys Comp.*, 1997, **249**, 146-152.
- 2 K. Matzumoto and J. Yuan, in *Metal Ions in Biological Systems: Vol 40: The Lanthanides and Their Interrelations with Biosystems. ed. Helmut Sigel & Astrid Sigel*, Marcel Dekker Inc., New York, 2003, vol. 40, pp. 191-226.
- 3 F. Leblond, S. C. Davis, P. A. Valdés and B. W. Pogue, J. Photochem. Photobiol. B: Biology, 2012, **98**, 77-94.
- 4 F. Wang, Y. Zhu, L. Zhou, L. Pan, Z. Cui, Q. Fei, S. Luo, D. Pan, Q. Huang, R. Wang, C. Zhao, H. Tian and C. Fan, *Angew. Chem. Int. Ed.*, 2015, **54**, 7349-7353.
- 5 M. Gao, F. Yu, C. Lv, J. Choo and L. Chen, *Chem. Soc. Rev.*, 2017, **46**, 2237-2271.

- 6 L. Wu and X. Qu, Chem. Soc. Rev., 2015, 44, 2963-2997.
- 7 H. He, Coord. Chem. Rev., 2014, **273-274**, 87-99.
- 8 Y. Cui, B. Chen and G. Qian, *Coord. Chem. Rev.*, 2014, **273–274**, 76-86.
- 9 Z. Liu, W. He and Z. Guo, Chem. Soc. Rev., 2013, 42, 1568-1600.
- 10 J.-C. G. Bunzli, Chem. Rev., 2010, 110, 2729-2755.
- T. Zhang, X. Zhu, C. C. W. Cheng, W.-M. Kwok, H.-L. Tam, J. Hao, D. W. J. Kwong, W.-K. Wong and K.-L. Wong, *J. Am. Chem.* Soc., 2011, **133**, 20120-20122.
- 12 H. Ke, W.-K. Wong, W.-Y. Wong, H.-L. Tam, C.-T. Poon and F. Jiang, *Eur. J. Inorg. Chem.*, 2009, 1243-1247.
- 13 S. Comby and J.-C. G. Bünzli, in *Handbook on the Physics and Chemistry of Rare Earths*, eds. J. Karl A. Gschneidner, J.-C. G. Bünzli and V. K. Pecharsky, Elsevier, 2007, vol. 37, pp. 217-470.
- 14 Z. Zhang, Y. Zhou, H. Li, T. Gao and P. Yan, *Dalton Trans*, 2019, 48, 4026-4034.
- 15 Q. Zhang, X. Yang, R. Deng, L. Zhou, Y. Yu and Y. Li, *Molecules*, 2019, **24**, 1253.
- 16 Y. Yao, H.-Y. Yin, Y. Ning, J. Wang, Y.-S. Meng, X. Huang, W. Zhang, L. Kang and J.-L. Zhang, *Inorg. Chem.*, 2019, **58**, 1806-1814.
- 17 H. P. Santos, E. S. Gomes, M. V. dos Santos, K. A. D'Oliveira, A. Cuin, J. S. Martins, W. G. Quirino and L. F. Marques, *Inorg. Chem. Acta*, 2019, **484**, 60-68.
- 18 K. Krekić, D. Klintuch, C. Lescop, G. Calvez and R. Pietschnig, Inorg. Chem., 2019, 58, 382-390.
- 19 Y. Ning, J. Tang, Y.-W. Liu, J. Jing, Y. Sun and J.-L. Zhang, *Chem. Sci.*, 2018, **9**, 3742-3753.
- 20 A. Loudet and K. Burgess, Chem. Rev., 2007, 107, 4891-4932.
- 21 N. Boens, V. Leen and W. Dehaen, *Chem. Soc. Rev.*, 2012, **41**, 1130-1172.
- 22 S. P. Singh and T. Gayathri, *Eur. J. Org. Chem.*, 2014, 4689-4707.
- 23 A. C. Benniston and G. Copley, *Phys. Chem. Chem. Phys.*, 2009, **11**, 4124-4131.
- 24 G. Ulrich, R. Ziessel and A. Harriman, *Angew. Chem. Int. Ed.*, 2008, **47**, 1184-1201.
- 25 C. Zhao, X. Zhang, K. Li, S. Zhu, Z. Guo, L. Zhang, F. Wang, Q. Fei, S. Luo, P. Shi, H. Tian and W.-H. Zhu, *J. Am. Chem. Soc.*, 2015, **137**, 8490-8498.
- 26 J. H. Ryu, Y. K. Eom, J.-C. G. Bunzli and H. K. Kim, *New J. Chem.*, 2012, **36**, 723-731.
- 27 R. F. Ziessel, G. Ulrich, L. Charbonnière, D. Imbert, R. Scopelliti and J.-C. G. Bünzli, *Chem. Eur. J.*, 2006, **12**, 5060-5067.
- 28 H. He, L. Si, Y. Zhong and M. Dubey, *Chem. Commun.*, 2012, 48, 1886-1888.
- 29 Y. Zhong, L. Si, H. He and A. G. Sykes, *Dalton Trans.*, 2011, **40**, 11389-11395.
- 30 H. He, J. D. Bosonetta, K. A. Wheeler and S. P. May, *Chem. Comm.*, 2017, 10120--10123.
- 31 M. Yanagida, R. Katoh, L. P. Singh, A. Islam, M. K. Nazeeruddin, K. Sayama, H. Sugihara, a. M. Grätzel, K. Hara and H. Arakawa, *Dalton Trans.*, 2000, 2817-2822.
- 32 G. M. Sheldrick, in SADABS, Empirical Absorption Correction Program; University of Göttingen, Germany, 1997.
- 33 G. M. Sheldrick, in SHELXTLTM, Reference manual, Version 5.1 Madison, WI, 1997.

- 34 M. J. T. Frisch, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, N. J.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J., Gaussian, Inc., Wallingford CT, 2009.
- 35 N. M. O'Boyle, A. L. Tenderholt and K. M. Langner, J. Comp. Chem., 2008, 29, 839-845.
- 36 M. Yanagida, L. P. Singh, K. Sayama, K. Hara, R. Katoh, A. Islam,
 H. Sugihara, H. Arakawa, M. K. Nazeeruddin and M. Grätzel,
 Dalton Trans, 2000, 2817-2822.
- 37 A. Cui, X. Peng, J. Fan, X. Chen, Y. Wu and B. Guo, J. Photochem. Photobiol. A: Chem., 2007, **186**, 85-92.
- 38 N. M. Shavaleev, R. Scopelliti, F. Gumy and J.-C. G. Bunzli, Inorg. Chem, 2009, 48, 7937-7946.
- 39 A. Aebischer, F. Gumy and J.-C. G. Bunzli, *Phys. Chem. Chem. Phys.*, 2009, **11**, 1346-1353.
- 40 L. Zhang and J. M. Cole, ACS Appl. Mater. Interfaces, 2015, 7, 3427-3455.
- 41 41. B. Le Guennic, O. Maury and D. Jacquemin, *Phys. Chem. Chem. Phys.*, 2012, **14**, 157-164.
- 42 W. Wu, H. Guo, W. Wu, S. Ji and J. Zhao, J. Org. Chem., 2011, 76, 7056-7064.



260x101mm (144 x 144 DPI)